03:00:07 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2023-11-17 Bokslutskommuniké 2023
2023-07-18 Kvartalsrapport 2023-Q3
2023-05-17 Kvartalsrapport 2023-Q2
2023-02-17 Kvartalsrapport 2023-Q1
2023-02-14 Årsstämma 2023
2023-02-10 Ordinarie utdelning CSMED 0.00 DKK
2022-11-18 Bokslutskommuniké 2022
2022-08-13 Kvartalsrapport 2022-Q3
2022-05-20 Kvartalsrapport 2022-Q2
2022-02-18 Kvartalsrapport 2022-Q1
2021-12-10 Ordinarie utdelning CSMED 0.00 DKK
2021-12-09 Årsstämma 2022
2021-11-18 Bokslutskommuniké 2021


ListaSpotlight DK
IndustriLäkemedel & Handel
CS Medica är ett danskt bolag verksamma inom medicinteknik. Bolaget är specialiserade inom utveckling av medicintekniska produkter. Portföljen inkluderar produkter som innehåller medicinsk cannabis (CBD), med störst inriktning mot kosttillskott och diverse behandlingsvård. Produkterna används exempelvis av patienter som lider av psoriasis, artros och håravfall. Störst verksamhet återfinns inom den nordiska marknaden, där produkterna vidaresäljs under eget varumärke.
2022-08-22 15:09:49

CS MEDICA ("CS Medica" or the "Company") announces today that the Company has extended its cooperation with its partner Nutrin, manufacture and R&D partner. Nutrin has developed a lozenge that protects against COVID-19 infection. This lozenge in combination with CS MEDICA's Protective Nasal Gel forms a shield that protects against COVID-19 virus infection.

Lone Henriksen, CEO of CS MEDICA, pronounces:

"I am very pleased to announce that CS MEDICA has expanded their product portfolio now also covering protection against COVID-19 virus infection. This opens a new market for the Company which has a huge market potential with the fall being just around the corner and thereby also a season for COVID-19."

The development and results on COVID-19
Nutrin has developed lozenge which has shown very good result in fighting COVID-19 and has now decided to initiate a promotion of lozenges together with CS MEDICA's Protective Nasal Gel in the fight of COVID-19 virus infection.

Result from lozenges against COVID-19 virus is shown below:

[image] Figure: Effects of Infect Protect Lozenges containing Sanddorn at various concentrations on SARS-CoV-2 pseudotyped virus infection

The lozenge's effect on COVID-19 is very convincing and therefore, CS MEDICA has decided to extend the cooperation with Nutrin by taken in these lozenges in their own brand CANNASEN® Infect Protect Lozenges as white label. The lozenges has an oral application, therefore CBD is not present in the lozenges, as this is illegal.

Protective Nasal Gel & Lozenges function
CS MEDICA sees a great opportunity to enter the COVID-19 protection market with the combination of the Protective Nasal Gel and Infect Protect Lozenges. Both the Nasal Gel and the Lozenge protect against COVID-19 by creating a barrier/shield in the nose and in the throat, which the COVID-19 virus can't get through and hereby the body is protected against the COVID-19 virus.

COVID-19 Protection Market and the Company's market share
The global COVID-19 Protection Market is valued at 138,4 Billion US$ in 2022 and is expected to increase with a CAGR% of 3,4%, to 163,5 billion US$ in 2027.[1] As the market is huge and also covers - Personal protective equipment, disinfectants and diagnostic supplies  - the company expects to only obtain a very small market share of 0,0127% corresponding to a value of 130,95 MDKK/Yearly after full rollout. This is because CS MEDICA cannot enter the following markets: Switzerland, Germany, Turkey, Greece, Austria - they are excluded from the cooperation. For each market, CS MEDICA is entering with the Lozenges a supply agreement is made with Nutrin for these countries.

Cooperation with Nutrin
CS MEDICA has cooperated with Nutrin GmbH since 2016. The company has since 13 January 2020, a manufacturing contract with Nutrin GmbH. The object of the contract is the production of the medical devices products (within the meaning of Section 3 No. 1 of the Medical Devices Act (MPG) and Art. 1 Para. 2 a) of the Medical Device Directive 93/42 / EEC (MDD) by Nutrin GmbH on behalf of the Company. This contract also defines the Quality Agreement between the parties in accordance with ISO 13485 and MDD.

Some statements may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential distributor agreements) are forward-looking statements. Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, which may cause the actual results of the Company to differ materially from those discussed in the forward looking statements. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described, there may be other factors that cause results or events not to be as anticipated, estimated or intended. The forward-looking statements included in this report are made as of the date of this press release and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

[1] https://www.mordorintelligence.com/industry-reports/veterinary-pain-management-market